C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects

Therapeutic Drug Monitoring

Volumn 24, Issue 3, 2002, Pages 400-404

  Min, David I ^a   Ellingrod, Vicki L ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Cyclosporine; MDRI gene mutation; P glycoprotein; Pharmacokinetics

Indexed keywords

CYCLOSPORIN A; MULTIDRUG RESISTANCE PROTEIN 1; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG METABOLISM; EXON; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; MALE; MULTIDRUG RESISTANCE; NORMAL HUMAN; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; ADOLESCENT; BLOOD; DOSE RESPONSE; GENETICS; ORAL DRUG ADMINISTRATION; POINT MUTATION; REFERENCE VALUE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXONS; FEMALE; GENOTYPE; HUMAN; IMMUNOSUPPRESSIVE AGENTS; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM (GENETICS); REFERENCE VALUES; SUPPORT, U.S. GOV'T, P.H.S.; HUMANS; POLYMORPHISM, GENETIC;

EID: 0036001238     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200206000-00012     Document Type: Article

References (25)

1. Reactions and significance of cytochrome P-450 enzymes
2. Drug metabolism by cytochromes P450 in the liver and small bowel
3. Enzymatic oxidation of xenobiotic chemicals
4. CYP3A activity in African American and European American Men: Population differences and functional effect of the CYP3A4*IB 5′-promotor region polymorphism
5. Pharmacological insights from P-glycoprotein knockout mice
6. P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans
7. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
8. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
9. Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs
10. P-glycoprotein and drug therapy in organ transplantation
11. Role of intestinal p-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
12. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient
13. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
14. Rapid detection of the C3435T polymorphism of multidrug resistance gene 1 using fluorogenic hybridization probes
15. Liquid-chromatographic determination of cyclosporine A in blood and plasma
16. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes
17. Inhibition of Pglycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine
18. The mdr1 gene product Pglycoprotein mediates the transport of the cardiac glycoside, digoxin
19. Idendification of functionally variant MDR1 alleles among European Americans and African Americans
20. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability
21. Cyclosporine bioavailability: Dosing implications and impact on clinical outcomes in select transplantation subpopulations
22. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers
23. Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects
24. Is it sex or is it gender?
25. Factors influencing the pharmacokinetics of cyclosporine in man